

Amendments to the Claims

The following listing of claims replaces all prior versions of claims in the application:

1-22. Cancelled.

23 (new). A pharmaceutical composition comprising a therapeutically effective amount of an (S)-pramipexole monobasic benzene sulfonic acid salt and at least one pharmaceutically acceptable carrier or diluent.

24 (new). The pharmaceutical composition according to claim 23, wherein said (S) pramipexole salt is at least substantially optically pure.

25 (new). The composition according to claim 23, wherein said composition contains from 0.088 mg to 0.88 mg, in terms of pramipexole free base, of said (S)-pramipexole salt.

26 (new). The composition according to claim 23, wherein said composition is in the form of a tablet.

27 (new). A process for treating schizophrenia, Parkinson's disease, Parkinsonism, hypertension, or depression, which comprises administering an effective amount of an (S)-pramipexole monobasic benzene sulfonic acid salt to a patient in need thereof.